Acetyl-L-Carnitine Boosts Effectiveness of Alzheimer's
Treatments
A new study indicates that Acetyl-L-carnitine
(ALC) can help improve cognitive function, ability to function,
and behavioral symptoms in Alzheimers patients who had not
responded to treatment with acetylcholinesterase inhibitors (AChE-I).
Past studies have shown that ALC has nerve-protective properties
and it has recently been shown to reduce attention deficits in
patients with Alzheimers disease after long-term treatment.
In the current study, researchers evaluated the effects of 2
grams daily of oral ALC for 3 months in 23 patients with mild
Alzheimers. The subjects also took their standard Alzheimers
medications, donepezil or rivastigmine. Study subjects had not
responded to treatment with acetylcholinesterase inhibitors (AChE-I).
Researchers evaluated the efficacy of ALC by assessing the level
of improvement in cognitive functions, functional status and
behavioral symptoms. When the patients had been given AChE-I
treatment without the ALC, 38% of the subjects improved. After
treatment with ALC, 50% of the Alzheimers patients experienced
improvement. The researchers concluded that combining ALC with
traditional treatments may be a useful therapeutic option in
Alzheimers patients.
Highly recommended
source of nutrients and supplements.
How
did we qualify VRP?
Reference:
Bianchetti, A, Rozzini R, Trabucchi M. Effects of Acetyl-L-Carnitine
In Alzheimers Disease Patients Unresponsive to
Acetylcholinesterase Inhibitors. Curr Med Res Opin. 2003;
19(4):350-353.
This study indicates that people at risk for Alzheimers disease
and Alzheimers disease patients may benefit from VRPs Acetyl-L-Carnitine
supplements.
|
